Cadrenal Therapeutics, Inc. announced on February 6, 2025, the appointment of James J. Ferguson, M.D., FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson brings over 25 years of leadership experience in cardiovascular medicine to the role.
In his new position, Dr. Ferguson will be responsible for leading the review of business development opportunities to expand the company’s pipeline. He will also drive the late-stage clinical development of tecarfarin for conditions requiring chronic anticoagulation therapy.
This leadership transition is expected to strengthen Cadrenal's strategic and development capabilities. The company aims to leverage Dr. Ferguson's expertise to advance tecarfarin and potentially add new assets to its portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.